BIF adds BioOra to its investment portfolio

Page 1 of 1



13 December 2024
Booster Innovation Fund adds BioOra to its investment portfolio

Booster is pleased to announce the addition of BioOra to the Booster Innovation Fund (BIF) portfolio.

BioOra operates in the human health part of the life sciences and medical technologies sector. It
specialises in automating the CAR T-cell therapy manufacturing process to reduce patient costs and
increase accessibility. BioOra was formed in 2021, and is classified as early stage, with its technology
origins being from Malaghan Institute of Medical Research (MIMR).

BIF will make a cash investment of $400,000 (and issue of additional units to fund the purchase), BioOra
will represent 2.0% of BIF’s investment portfolio of 36 active companies, and with a net asset value of
over $20.4m.

Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of
the process described in the fund’s Product Disclosure Statement (PDS) that is available at
www.booster.co.nz.

For further information regarding BIF visit https://www.booster.co.nz/booster-investments/booster-
innovation-fund.aspx





For more information, please contact:
Gary Scott
Company Secretary
Booster Investment Management Limited
04 8944300


About Booster
Booster Investment Management Limited (Booster) is the manager and issuer of the Fund, and part of
the Booster Group which has been helping New Zealanders save since 1998. The group currently
administers superannuation and investment funds of over $7 billion on behalf of more than 200,000 New
Zealanders.
BIF is a managed investment fund that invests in early-stage companies founded on intellectual property
originated or developed in New Zealand.
For more information, including a copy of the Product Disclosure Statement, please visit
www.booster.co.nz